ACAD vs DXCM
ACADIA Pharmaceuticals Inc. vs Dexcom — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
67
Buy
VS
| Metric | ACAD | DXCM |
|---|
| AI Score |
67
|
63
|
| Price |
$30.59
|
$89.16
|
| P/E Ratio |
13.18×
|
35.16×
|
| ROE |
31.9%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
62.5%
|
| Debt / Equity |
0.06×
|
0.53×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
61.2
|
65.4
|
| Beta |
0.845
|
1.41
|
| Expected Upside |
—
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus DXCM.
ACAD leads by 4 points.
ACAD scores 67/100 (Buy) versus DXCM at 63/100 (Buy).
ACAD Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
DXCM Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- RSI at 75 is in overbought territory — Technical